1. Home
  2. TMC vs ABCL Comparison

TMC vs ABCL Comparison

Compare TMC & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TMC the metals company Inc.

TMC

TMC the metals company Inc.

HOLD

Current Price

$4.48

Market Cap

1.8B

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$10.31

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMC
ABCL
Founded
2011
2012
Country
Canada
Canada
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
TMC
ABCL
Price
$4.48
$10.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$8.85
$8.40
AVG Volume (30 Days)
4.1M
6.7M
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
232.00
10.91
EPS
0.05
N/A
Revenue
N/A
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$21.85
P/E Ratio
$91.00
N/A
Revenue Growth
N/A
160.56
52 Week Low
$3.40
$2.75
52 Week High
$11.35
$10.29

Technical Indicators

Market Signals
Indicator
TMC
ABCL
Relative Strength Index (RSI) 58.36 80.10
Support Level $4.24 $3.38
Resistance Level $4.89 N/A
Average True Range (ATR) 0.24 0.65
MACD 0.14 0.51
Stochastic Oscillator 80.52 98.96

Price Performance

Historical Comparison
TMC
ABCL

About TMC TMC the metals company Inc.

TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: